臨床研究等提出・公開システム

A phase 1 study of self-amplifying mRNA vaccine VLPCOV-01
Randomized, placebo-controlled, parallel group, first-in-human study (FIH Study)(COVID-19)

A phase 1 study of self-amplifying mRNA vaccine VLPCOV-01
Randomized, placebo-controlled, parallel group, first-in-human study (FIH Study)(COVID-19)

Sato Nobuaki

VLP Therapeutics Japan, LLC

Hilton Plaza West Office Tower, 2-2-2 Umeda Kita-ku, Osaka city, Osaka

clinical@vlptherapeutics.com

Clinical Development

VLP Therapeutics Japan, LLC

Hilton Plaza West Office Tower, 2-2-2 Umeda Kita-ku, Osaka city, Osaka

+81-70-8336-6345

clinical@vlptherapeutics.com

Complete

Sept. 27, 2021

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

prevention purpose

1. Healthy Japanese male and female subjects who are 20 to 65 years of age.
2. Participants who understand and agree to comply with the study procedures and provide written informed consent.
3. Participants whose BMI is 18-35 kg/m^2.
4. Participants whose body temperature is below 37.5 degree Celsius at screening.
5. Participants who have negative PCR test results SARS-CoV-2 at screening.
6. Participants who is willing and able to keep diary by himself/herself.

1. Female participants who are confirmed or suspected pregnant, planned to be pregnant within 90 days of the last vaccination, or lactating.
2. Participants who are judged inappropriate in their health condition by Principal investigator or Sub-investigator.
3. Participants who have known history of COVID-19.
4. Participants who have history of COVID-19 vaccination, including investigational vaccine (exclusion placebo).
5. Participants who have history of significant diseases of cardiac, vascular system (including thrombosis), blood, respiratory, hepatic, renal, GI, psychiatric diseases or disorders.
6. Participants who have history of allergy such as systemic skin rash.
7. Participants who have history of convulsion (including febrile convulsions), Guillain-Barre syndrome, acute disseminated encephalomyelitis.
8. Participants who were diagnosed immune system disorder.
9. Participants who are receiving or scheduling any medicine and/or therapy that could interfere with immunogenicity assessment of test medications.
10. Participants who have history of anaphylaxis caused by food or medicines.
11. Participants who have history or risk of allergy or anaphylaxis caused by any components of study medications.
12. Participants who received any investigational product or vaccine 28 days prior to screening of this study, or who are planning to join any other investigation study during this study.
13. Participants who are bleeding tendency and considered a contraindication to intramuscular injection by Principal investigator or Sub-investigator.
14. Participants who received investigational product or medicine that contains lipid nano particle.

Both

Prevention of infectious disease caused by SARS-CoV-2

VLPCOV-01 0.5 mL or VLPCOV-01 Matching Placebo, intramuscular injection in the upper arm

Frequency and severity of solicited local and systemic reactogenicity AEs for 7 days following each vaccination.
Frequency and severity of unsolicited AEs until 28 days after last vaccination.

+81-97-549-4411

Aug. 02, 2021

No

none